Discover 522 paid clinical trials in Memphis, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 522
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
for
Melanoma
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 0 - 18
Code: NCT02775643
Recruiting
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
for
Sickle Cell Disease, Vaso-occlusive Crisis
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 6 - 25
Code: NCT03353584
Recruiting
Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility
for
Normal and Diseased Tissue and Body Fluids Samples
Location: Memphis TN, Huntsville AL, Springfield MO,
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 0+
Code: NCT01354002
Recruiting
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).
for
Gastro-Intestinal Disorder
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 0 - 22
Code: NCT05664113
Phase1, Recruiting
Childhood Cancer Predisposition Study (CCPS)
for
Pediatric Cancer
Location: Memphis TN, Atlanta GA, Houston TX, Toronto,
Sponsor: Emory University
Sex: All
Age: 0+
Code: NCT04511806
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Location: Memphis TN, Little Rock AR, Nashville TN, Jackson MS,
Sponsor: Children's Oncology Group
Sex: All
Age: 3 - 29
Code: NCT06368817
Phase2, Recruiting
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Location: Memphis TN, Birmingham AL, St Louis MO, Atlanta GA,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 30
Code: NCT04851119
Phase1, Phase2, Recruiting
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
for
Acute Lymphoblastic Leukemia,
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 0 - 21
Code: NCT06777979
Phase1, Recruiting
Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
for
Relapsed Hematologic Malignancy,
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 0+
Code: NCT05713214
Recruiting
Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition
for
Genetic Predisposition
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 10 - 24
Code: NCT05849155
Recruiting
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
for
HIV Infection
Location: Memphis TN, Chicago IL, Houston TX, Jacksonville FL,
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All
Age: 0
Code: NCT02140255
Phase1, Phase2, Recruiting
Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
for
Solid Tumor
Location: Memphis TN, Chicago IL, Pittsburgh PA
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 0 - 20
Code: NCT05645523
Early_phase1, Recruiting
International Pediatric Adrenocortical Tumor Registry
for
Adrenocortical Tumor
Location: Memphis TN, Dayton OH
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 0 - 21
Code: NCT00700414
Recruiting
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
for
Rhabdomyosarcoma
Location: Memphis TN, Palo Alto CA
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 0 - 22
Code: NCT06023641
Phase2, Recruiting
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer